The T3 Cleanrooms at Brisbane’s Translational Research Institute were officially launched on Wednesday.
The new facility was backed by a $500,000 grant from the federal government-funded MTPConnect Growth Centre, with the same amount invested by the TRI and in-kind support from Vaxxas, which is based at the institute.
TRI CEO Professor Scott Bell said the new facility met a critical gap for medtech manufacturing startups needing to scale-up for clinical trials and identified by Vaxxas.
“Having access to this vital facility is enabling Vaxxas to progress its innovative vaccine technology from preclinical to clinical trials, and is a great example of the translational pathway that exists at TRI to foster the commercialisation of Australian medical innovations,” said Bell.
Vaxxas is commercialising a needle-free vaccine delivery platform.
MTConnect managing director Dr Dan Grant said the facility would help companies like Vaxxas remain in Australia, as they would not have to take small-scale, early stage clinical product manufacturing for clinical trials overseas.
“It means we can keep our best and brightest innovators here in Australia and importantly, accelerate the translation of new innovations which lead to new jobs, economic growth and improved patient outcomes,” said Grant.
Subscribe to our free @AuManufacturing newsletter here.